L. Kuaban and . Vidal,

G. Maradan, A. Ambani, O. Ndalle, P. Momo, and C. Tong,

S. Boyer, V. Boyer, P. J. Coulaud, L. March, M. Mora et al., , p.912

C. Laurent, F. Liégeois, E. Delaporte, and S. Eymard-duvernay, A. Riondel (TransVIHMI

F. Chabrol, E. Kouakam, O. Ossanga, H. E. Owona, C. Biloa et al., UCAC

E. Mpoudi-ngolé,

P. J. Fouda, C. Kouanfack, H. Abessolo, N. Noumssi, M. Defo et al.,

Z. Nanga, Y. Perfura, M. Ngo-tonye, O. Kouambo, U. Olinga et al.,

C. Ejangue, E. Nlend, A. Simo, and . Ndongo,

M. E-abeng-mbozo'o, N. Ngole, C. Manga, L. Danwe, B. Ayangma et al.,

E. C. Njitoyap-ndam, B. Molu, J. Meli, H. Hadja, and J. Lindou, Hôpital Général

J. M. Bob-oyono and S. Beke,

D. Eloundou and G. Touko, District Hospital

J. J. Ze, M. Fokoua, L. Ngum, C. Ewolo, and C. Bondze, District Hospital

J. D. Bilong, D. S. Maninzou, and A. Toche,

M. Akoa, P. Ateba, and S. Abia, Mbalmayo

A. Guterrez, R. Garcia, and P. Thumerel, Bikop

E. Belley-priso, A. Mapoure, A. P. Malongue, B. Ndjong, J. Mbatchou et al.,

J. Dissongo, M. Mbangue, I. Penda, H. Mossi, G. Tchatchoua et al.,

M. J. Gomez, A. Mafuta, and M. Mgantcha, Catholic Hospital

E. H. Moby, M. C. Kuitcheu, and A. L. Mawe, Ngam Engonwei (District Hospital

L. J. Bitang, M. Ndam, and R. B. Pallawo, Issiakou Adamou, G.Temgoua (District Hospital

C. Essaga, C. Tchimou, A. Yeffou, I. Ngo, H. Fokam et al., District Hospital

L. R. Njock, S. Omgnesseck, E. Kamto, and B. Takou, District Hospital

L. Buffeteau, F. Ndoumbe, I. Noah, and . Seyep,

, World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis, 2016.

C. W. Spearman, M. Afihene, A. R. Apica, B. Awuku, Y. Cunha et al., Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets, Lancet Gastroenterol Hepatol, vol.2, pp.900-909, 2017.

, World Health Organization. Global hepatitis report, 2017.

S. Leumi, J. J. Bigna, M. A. Amougou, A. Ngouo, U. F. Nyaga et al., Global burden of hepatitis B infection in people living with HIV: a systematic review and meta-analysis, Clin Infect Dis, 2019.

, Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2010.

, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, 2016.

, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013.

P. A. Coffie, M. Egger, M. J. Vinikoor, M. Zannou, L. Diero et al., Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa, BMC Infect Dis, vol.17, p.706, 2017.

C. Kouanfack, A. F. Aghokeng, A. M. Mondain, A. Bourgeois, A. Kenfack et al., Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon, Antivir Ther, vol.17, pp.321-327, 2012.

B. Stewart, M. L. Jobarteh, R. Sarge-njie, A. Alabi, T. De-silva et al., Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in the Gambia, BMC Res Notes, vol.4, p.561, 2011.

C. Laurent, A. Bourgeois, E. Mpoudi-ngole, C. Kouanfack, L. Ciaffi et al., High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy, HIV Med, vol.11, pp.85-94, 2010.

A. Zoufaly, E. F. Onyoh, P. M. Tih, C. N. Awasom, and T. Feldt, High prevalence of hepatitis B and syphilis co-infections among HIV patients initiating antiretroviral therapy in the north-west region of Cameroon, Int J STD AIDS, vol.23, pp.435-443, 2012.

J. P. Molu, M. Essome, C. G. Monamele, and R. Njouom, Sero-prevalence of HBsAg in naive HIV-infected patients in a rural locality of Cameroon, BMC Res Notes, vol.11, p.39, 2018.

, Directives nationales de prise en charge par les antirétroviraux des personnes (adultes et adolescents) infectées par le VIH. Yaoundé, 2010.

F. Liegeois, S. Eymard-duvernay, S. Boyer, G. Maradan, C. Kouanfack et al., Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM), HIV Med, vol.20, pp.38-46, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02456788

S. Boyer, F. Eboko, M. Camara, C. Abe, M. E. Nguini et al., Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon, AIDS, vol.24, issue.1, pp.5-15, 2010.

H. Price, D. Dunn, D. Pillay, F. Bani-sadr, T. De-vries-sluijs et al., Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis, PLoS One, vol.8, p.68152, 2013.

C. Trepo, H. L. Chan, and A. Lok, Hepatitis B virus infection, Lancet, vol.384, pp.2053-63, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02370703

C. J. Hoffmann and C. L. Thio, Clinical implications of HIV and hepatitis B coinfection in Asia and Africa, Lancet Infect Dis, vol.7, pp.402-411, 2007.

V. T. Nguyen, M. G. Law, and G. J. Dore, Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden, J Viral Hepat, vol.16, pp.453-63, 2009.

, Ministry of Public Health. National guideline on the prevention and management of HIV in Cameroon, 2015.

G. Ndow, M. L. Gore, Y. Shimakawa, P. Suso, A. Jatta et al., Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes, PLoS One, vol.12, p.179025, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01570239

M. J. Vinikoor, K. Musukuma, V. Munamunungu, M. Masaninga, I. Sikazwe et al., Implementation of routine screening for chronic hepatitis B virus co-infection by HIV clinics in Lusaka, Zambia, J Viral Hepat, vol.22, pp.858-60, 2015.

R. Nuesch, J. Ananworanich, P. Srasuebkul, P. Chetchotisakd, W. Prasithsirikul et al., Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection, AIDS, vol.22, pp.152-156, 2008.

M. Bessesen, D. Ives, L. Condreay, S. Lawrence, and K. E. Sherman, Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine, Clin Infect Dis, vol.28, pp.1032-1037, 1999.

, World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, 2015.

M. J. Mphahlele, A. Lukhwareni, R. J. Burnett, L. M. Moropeng, and J. M. Ngobeni, High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa, J Clin Virol, vol.35, pp.14-20, 2006.

K. Ryan, M. Anderson, I. Gyurova, L. Ambroggio, S. Moyo et al., High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana, Open Forum Infect Dis, vol.4, p.195, 2017.

M. Anderson, S. Gaseitsiwe, S. Moyo, K. P. Thami, T. Mohammed et al., Slow CD4(+) T-Cell Recovery in Human Immunodeficiency Virus/ Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana, Open Forum Infect Dis, vol.3, p.140, 2016.

M. J. Vinikoor, E. Sinkala, R. Chilengi, L. B. Mulenga, B. H. Chi et al., Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV Coinfection in Zambia, Clin Infect Dis, vol.64, pp.1343-1352, 2017.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations